The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG’s phase III trials N9741 and N9841.
J. Franko
No relevant relationships to disclose
Q. Shi
No relevant relationships to disclose
C. D. Goldman
No relevant relationships to disclose
B. A. Pockaj
No relevant relationships to disclose
G. D. Nelson
No relevant relationships to disclose
R. M. Goldberg
Consultant or Advisory Role - Genentech; Lilly
Research Funding - Abbott Laboratories; Amgen; Bayer; Bristol-Myers Squibb; Genentech; Sanofi
H. C. Pitot
No relevant relationships to disclose
A. Grothey
No relevant relationships to disclose
S. R. Alberts
Consultant or Advisory Role - Merck Serono (U)
Research Funding - Bristol-Myers Squibb
D. J. Sargent
No relevant relationships to disclose